|drug898||Convalescent Plasma 1 Unit Wiki||1.00|
|drug1302||Favipiravir + Standard of Care Wiki||1.00|
|drug3221||Standard of Care Wiki||0.16|
|D012327||RNA Virus Infections NIH||0.41|
|D014777||Virus Diseases NIH||0.11|
|D003141||Communicable Diseases NIH||0.08|
There is one clinical trial.
This is a prospective study, involving contacting potential plasma donors and the use of their plasma to help fight off infections of those suffering from COVID19 in accordance to collection guidelines for plasma and FDA IND requirement. This study will include up to 240 participants potentially receiving convalescent plasma and up to 1000 potential donors. There are 3 basic arms to the study: mild, moderate and severe/critical severity. All 3 severity groups are eligible for enrollment, but mild severity will not be given plasma unless there is progression. Moderate severity will given up to 1 unit of plasma and severe/critical severity up to 2 units. There is no placebo group, however given the excepted issues of shortages of plasma, intention to treat will be used for analysis.
Description: Time it takes to identify eligible donors whom are willing to donateMeasure: Plasma Donor Time: Measured in days for 365 days
Description: Time it takes the plasma collection center to contact willing donors whom are allowed to donate plasmaMeasure: Plasma Donor Time: Measured in days for 365 days
Description: Time from consent to infusionMeasure: Plasma Recipient Time: Measured evey 24 hours up to 30 days
Description: SurvivalMeasure: Plasma Recipient Time: Measured in days with 30 day from discharge follow-up
Description: Time until plasma is donatedMeasure: Plasma Donor Time: Measured every 24 hours up to 1 year
Description: Incident of treatment-Emergent Adverse Events [Safety and Tolerability]Measure: Plasma Recipient Time: Day 1, 2, 3, 4, 7, and 30 day
Description: Morbidity reductionMeasure: Plasma Recipient Time: Day 1, 2, 3, 4, 7, and 30 day
Description: Reduced Length of Stay in hospitalMeasure: Plasma Recipient Time: Measured every 24 hours until patient discharged from hospital up to 1 year
Description: Reduced Length of Stay on Advance Respiratory SupportMeasure: Plasma Recipient Time: Measured every 24 hours until Off Advanced Respiratory Support up to 1 year
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports